Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2024-07-01

FDA Approved: NINLARO — Supplemental Application (Takeda Pharmaceuticals America, Inc.)

View source ↗

Summary

FDA approved a supplemental application for NINLARO (ixazomib) submitted by Takeda Pharmaceuticals America, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • NINLARO (ixazomib)

Snippet

SUPPL AP for NINLARO (IXAZOMIB)